SCHEMBL5266873

SCHEMBL5266873

CC(NCc1ccc(-c2ccccc2)cc1)c1ccc(Cl)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
LMNA P02545 2/20 0.45
HTT P42858 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPK1 P28482 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
ADRB2 P07550 1/20 0.44
CYP1A2 P05177 3/20 0.44
CYP2D6 P10635 3/20 0.44
CYP2C19 P33261 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.42
AKT1 P31749 1/20 0.42
TP53 P04637 1/20 0.41
ADAMTS5 Q9UNA0 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
MEN1 O00255 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5266871 1.00 POLB (0.46) POLBLMNAHTTALDH1A1MAPK1
SCHEMBL5272037 0.91 POLB (0.54) POLBLMNAHTTCYP1A2CYP2D6
SCHEMBL5270032 0.91 POLB (0.54) POLBLMNAHTTCYP1A2CYP2D6
SCHEMBL5269101 0.89 CASR (0.46) POLBLMNAHTTCYP1A2CYP2D6
SCHEMBL5267525 0.89 POLB (0.46) POLBLMNAHTTALDH1A1MAPK1
SCHEMBL5270951 0.85 POLB (0.54) POLBLMNAHTTALDH1A1MAPK1
SCHEMBL5271170 0.85 TDP1 (0.45) POLBHTTALDH1A1MAPK1NPSR1
SCHEMBL5268041 0.84 SMN1; SMN2 (0.49) POLBLMNAHTTALDH1A1NPSR1
SCHEMBL5270321 0.84 LMNA (0.45) POLBLMNAHTTCYP1A2CYP2D6
SCHEMBL5270108 0.84 ALDH1A1 (0.48) POLBLMNAHTTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074539-B1 Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL CO (JP) 2007-10-17 EP disclosed
US-6894190-B2 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-05-17 US disclosed
US-20030232886-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2003-12-18 US disclosed
US-6653507-B2 Useful intermediate compound of pharmaceuticals for urinary incontinence SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-11-25 US disclosed
US-20020143212-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED 2002-10-03 US disclosed
US-6403832-B1 MIXING ACID WITH AMINE, PRECIPITATING SALT, AND FILTERING; GOOD OPTICAL PURITY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-06-11 US disclosed
EP-1074539-A2 Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2001-02-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232886-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof ALDH1A2, CYP8B1, CYP11B2 POLB 2783/4885LMNA 1166/4885HTT 1573/4885
US-20020143212-A1 Process for producing optically active 3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof ALDH1A2, ALDH7A1, ALDH18A1 POLB 3732/4885LMNA 1926/4885HTT 2777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.